Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)
Close on Nov 17, 2026Market cap $4.78MP/E –Yield –
Cerenome EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cerenome's EPS for the twelve months ending Sep 30, 2025 was -$48.94. For fiscal 2025 it was -$7.25. The highest annual figure on record is -$7.25 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.25 | – |
| FY2024 | Dec 31, 2024 | -$58.50 | – |
| FY2023 | Dec 31, 2023 | -$106.00 | – |
| FY2022 | Dec 31, 2022 | -$289.50 | – |
| FY2021 | Dec 31, 2021 | -$416.25 | – |
| FY2020 | Dec 31, 2020 | -$697.50 | – |
| FY2019 | Dec 31, 2019 | -$3101.25 | – |
| FY2018 | Dec 31, 2018 | -$32617.50 | – |
| FY2017 | Dec 31, 2017 | -$154312.50 | – |
| FY2016 | Dec 31, 2016 | -$240000.00 | – |
| FY2015 | Dec 31, 2015 | -$388125.00 | – |
| FY2014 | Dec 31, 2014 | -$1350000.00 | – |
| FY2013 | Dec 31, 2013 | -$1096875.00 | – |
| FY2012 | Dec 31, 2012 | -$1546875.00 | – |
| FY2011 | Dec 31, 2011 | -$1715625.00 | – |
| FY2010 | Dec 31, 2010 | -$1687500.00 | – |
| FY2009 | Dec 31, 2009 | -$1828125.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.31 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.05 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.00 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.16 | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.86 | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.92 | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.25 | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.75 | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.75 | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.17 | – |
| Q3 FY2023 | Sep 30, 2023 | -$25.00 | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.75 | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.75 | – |
| Q4 FY2022 | Dec 31, 2022 | -$63.05 | – |
| Q3 FY2022 | Sep 30, 2022 | -$71.25 | – |
| Q2 FY2022 | Jun 30, 2022 | -$89.00 | – |
| Q1 FY2022 | Mar 31, 2022 | -$71.25 | – |
| Q4 FY2021 | Dec 31, 2021 | -$100.70 | – |
| Q3 FY2021 | Sep 30, 2021 | -$105.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$93.75 | – |
| Q1 FY2021 | Mar 31, 2021 | -$123.75 | – |
| Q4 FY2020 | Dec 31, 2020 | -$250.45 | – |
| Q3 FY2020 | Sep 30, 2020 | -$146.25 | – |
| Q2 FY2020 | Jun 30, 2020 | -$168.75 | – |
| Q1 FY2020 | Mar 31, 2020 | -$105.00 | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.25 | – |
| Q2 FY2019 | Jun 30, 2019 | -$7751.25 | – |
| Q1 FY2019 | Mar 31, 2019 | -$3345.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$3021.62 | – |
| Q1 FY2018 | Mar 31, 2018 | -$13687.50 | – |
| Q4 FY2017 | Dec 31, 2017 | -$37500.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$26062.50 | – |
| Q2 FY2017 | Jun 30, 2017 | -$36375.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$61875.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$45000.00 | – |
| Q3 FY2016 | Sep 30, 2016 | -$48750.00 | – |
| Q2 FY2016 | Jun 30, 2016 | -$80625.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?